| 1 |
33733978 | Immunomodulators in newly diagnosed multiple myeloma: current and future concepts. | 2021 Apr |
1 |
| 2 |
32435618 | The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma. | 2020 |
1 |
| 3 |
30826127 | Reprint of "Immunomodulatory effects of CD38-targeting antibodies". | 2019 Jan |
1 |
| 4 |
31043801 | Selective purging of human multiple myeloma cells from peripheral blood mononuclear cells: a preliminary study. | 2019 |
1 |
| 5 |
29702148 | Immunomodulatory effects of CD38-targeting antibodies. | 2018 Jul |
1 |
| 6 |
30079070 | CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. | 2018 |
1 |
| 7 |
28249894 | Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. | 2017 Aug 1 |
2 |
| 8 |
27611189 | Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity. | 2016 |
2 |
| 9 |
25398450 | Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. | 2015 Jun 15 |
1 |
| 10 |
27668268 | Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors. | 2015 Jun |
2 |